NRX Pharmaceuticals, Inc. financial data

Symbol
NRXP, NRXPW on Nasdaq
Location
1201 Orange Street, Suite 600, Wilmington, DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 20 %
Debt-to-equity -128 % +3.18%
Return On Equity 139 % -14.3%
Return On Assets -490 % +1.53%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28.1M shares +132%
Common Stock, Shares, Outstanding 27.7M shares +143%
Entity Public Float 21.5M USD -27.6%
Common Stock, Value, Issued 28K USD +155%
Weighted Average Number of Shares Outstanding, Basic 22.2M shares +103%
Weighted Average Number of Shares Outstanding, Diluted 8.85M shares +33.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 242K USD
Cost of Revenue 97K USD
Research and Development Expense 1.43M USD +134%
General and Administrative Expense 2.74M USD -35.4%
Costs and Expenses 4.27M USD +41.2%
Operating Income (Loss) -4.02M USD -33.2%
Nonoperating Income (Expense) -1.87M USD -233%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -38.1M USD -46.9%
Earnings Per Share, Basic -0.27 USD/shares -80%
Earnings Per Share, Diluted -0.74 USD/shares +55.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.18M USD +336%
Accounts Receivable, after Allowance for Credit Loss, Current 239K USD
Other Assets, Current 128K USD
Assets, Current 11.9M USD +191%
Property, Plant and Equipment, Net 69K USD
Operating Lease, Right-of-Use Asset 350K USD
Intangible Assets, Net (Excluding Goodwill) 1.78M USD
Goodwill 610K USD
Other Assets, Noncurrent 243K USD -31.7%
Assets 15M USD +236%
Accounts Payable, Current 4.26M USD -12.5%
Employee-related Liabilities, Current 420K USD +29.6%
Accrued Liabilities, Current 5.3M USD +4.79%
Liabilities, Current 40.6M USD +100%
Liabilities 40.8M USD +75%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -307M USD -14.1%
Stockholders' Equity Attributable to Parent -25.8M USD -36.8%
Liabilities and Equity 15M USD +236%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.48M USD +5.2%
Net Cash Provided by (Used in) Financing Activities 7.59M USD +1820%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 27.7M shares +143%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 4.11M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.32M USD -92%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 49.7M USD +10.6%
Deferred Tax Assets, Gross 44.9M USD +6.78%
Operating Lease, Liability 347K USD
Depreciation 2K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.89M USD -262%
Lessee, Operating Lease, Liability, to be Paid 375K USD
Property, Plant and Equipment, Gross 93K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 121K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 202K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 28K USD
Deferred Tax Assets, Operating Loss Carryforwards 39.8M USD +10.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Additional Paid in Capital 281M USD +12.4%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 197K USD -29.9%
Interest Expense 230K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%